

October 1, 2021

This HEDIS<sup>®1</sup> Measurement year (MY) 2021 Public Reporting memo outlines all measures, product lines and indicators that have been approved for public reporting for MY 2021, MY 2022 and MY 2023, as well as all measures, product lines and indicators that will not be publicly reported for MY 2021.

If you have questions about the information included in the tables, contact us through My NCQA (<https://my.ncqa.org>).

HEDIS Measurement Year	HEDIS Measures
2021	<p>The following first-year and first-year status measures, product lines and indicators will be publicly reported for MY 2021:</p> <ul style="list-style-type: none"> <li>• Cardiac Rehabilitation (CRE).</li> <li>• Osteoporosis Screening in Older Women (OSW).</li> <li>• Kidney Health Evaluation for Patients with Diabetes (KED).</li> <li>• Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)—Medicare.</li> <li>• Appropriate Treatment for Upper Respiratory Infection (URI)—Medicare.</li> <li>• Appropriate Testing for Pharyngitis (CWP)—Medicare.</li> <li>• Emergency Department Utilization (EDU).</li> <li>• Use of High-Risk Medication Use in Older Adults (DAE)—Rate 2 and Total Rate.</li> </ul>
2021	<p>The following measures reported using Electronic Clinical Data Systems (ECDS) will not be publicly reported for MY 2021:</p> <ul style="list-style-type: none"> <li>• Breast Cancer Screening (BCS-E).</li> <li>• Colorectal Cancer Screening (COL-E).</li> <li>• Follow-Up Care for Children Prescribed ADHD Medication (ADD-E).</li> <li>• Depression Screening and Follow-Up for Adolescents and Adults (DSF-E).</li> <li>• Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E).</li> <li>• Depression Remission or Response for Adolescents and Adults (DRR-E).</li> <li>• Unhealthy Alcohol Use Screening and Follow-Up (ASF-E).</li> <li>• Adult Immunization Status (AIS-E).</li> <li>• Prenatal Depression Screening and Follow-Up (PND-E).</li> <li>• Postpartum Depression Screening and Follow-Up (PDS-E).</li> </ul>

<sup>1</sup>HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA).

NCQA announces the recently approved public reporting decisions for the following measures reported using ECDS and the measurement year in which public reporting will take effect.

HEDIS Measurement Year	HEDIS Measures
2022	<p>The following measures reported using ECDS will be publicly reported for MY 2022:</p> <ul style="list-style-type: none"> <li>• Adult Immunization Status (AIS-E).</li> <li>• Prenatal Depression Screening and Follow-Up (PND-E).</li> <li>• Postpartum Depression Screening and Follow-Up (PDS-E).</li> </ul>
2023	<p>The following measures reported using ECDS will be publicly reported for MY 2023:</p> <ul style="list-style-type: none"> <li>• Depression Screening and Follow-Up for Adolescents and Adults (DSF-E).</li> <li>• Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E).</li> <li>• Depression Remission or Response for Adolescents and Adults (DRR-E).</li> <li>• Unhealthy Alcohol Use Screening and Follow-Up (ASF-E).</li> </ul>

---

## NCQA Copyright Notice and Disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. **Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program.** Reprinted with permission by NCQA. © 2021 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measure specifications.

The American Hospital Association holds a copyright to the Uniform Billing Codes ("UB") contained in the measure specifications. Any use of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact [ub04@aha.org](mailto:ub04@aha.org).

Some measure specifications contain coding from LOINC® (<http://loinc.org>). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright © 1995–2021 Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and are available at no cost under the license at <http://loinc.org/terms-of-use>.

"SNOMED" and "SNOMED CT" are registered trademarks of the International Health Terminology Standards Development Organisation (IHTSDO).

"HL7" is the registered trademark of Health Level Seven International.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without the written permission of NCQA.